Yayınlanmış 1 Ocak 2015
| Sürüm v1
Dergi makalesi
Açık
The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder
Oluşturanlar
- 1. Mersin Univ, Fac Pharm, Dept Pharmaceut Toxicol, Mersin, Turkey
- 2. Ankara Univ, Sch Med, Dept Psychiat, TR-06100 Ankara, Turkey
- 3. Kirikkale Univ, Fac Med, Dept Psychiat, Kirikkale, Turkey
- 4. Ankara Univ, Fac Pharm, Dept Toxicol, TR-06100 Ankara, Turkey
Açıklama
What is known and objective: Genetic variations in drug-metabolizing enzyme genes change drug pharmacokinetics and response. CYP2C19 is a clinically important enzyme that metabolizes citalopram (CIT). The objective of this study was to determine CYP2C19 genetic polymorphisms and to evaluate the impact of these polymorphisms on the metabolism of citalopram in a sample of the Turkish population. We also assessed *17 polymorphism in healthy subjects in this population.
Dosyalar
bib-c669cf85-4761-432a-adb6-004b5eb5b9d1.txt
Dosyalar
(251 Bytes)
| Ad | Boyut | Hepisini indir |
|---|---|---|
|
md5:8af07a2c57365ef2c2dfe472bb21a159
|
251 Bytes | Ön İzleme İndir |